Physician profile
Simon Li
NPI 1265751002
$7,308.78
in general payments reported to CMS, 2019-2025
26 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 91% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $261 · 2021: $1,374 · 2022: $809 · 2023: $1,176 · 2024: $1,802 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,614.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,905.73 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $1,767.65 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $860.15 | 2020-2025 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $487.05 | 2021 | |
| Amarin Pharma, INC. | $342.37 | 2020-2023 | |
| Exact Sciences Corporation | $313.42 | 2023-2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $293.72 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $174.43 | 2021-2022 | |
| Stryker Corporation | $166.67 | 2023 | Mako |
| Amgen INC. | $157.34 | 2023-2025 | Evenity, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $150.00 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.95 | 2021-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $107.41 | 2021-2023 | |
| Horizon Therapeutics Plc | $86.85 | 2021-2022 | |
| Pfizer INC. | $65.25 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.99 | 2020-2024 | Mounjaro, Zepbound |
| Progenics Pharmaceuticals, INC. | $49.68 | 2024 | |
| Hikma Pharmaceuticals USA | $38.99 | 2021 | |
| Vivus LLC | $22.39 | 2022 | |
| Eisai INC. | $22.22 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.96 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.97 | 2025 | Zoryve |
| Scilex Pharmaceuticals INC. | $19.83 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.78 | 2021 | |
| Merck Sharp & Dohme LLC | $16.22 | 2021 | |
| Allergan, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.